longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Evolus

EOLS

7.9701.40% ( +0.110 )
Closed: Sep 25, 15:59:59 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -15.12, below the reasonable range, cheaper than 88.51% of the time in the past 1 years, and the industry ranks 199/256, the industry Median -1.36.

-15.12xP/E
$7.86Stock price
$-0.52Earnings per share
-15.12xP/E
Stock price$7.86Earnings per share$-0.52

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-7.58x
Typical range
-10.21x–-5.83x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-56.25x149.86%$58.73B
BAYRYUSBayer
-27.50x--$55.49B
BAYZFUSBayer Aktiengesellschaft
-27.40x--$55.28B
VTRSUSViatris
-48.72x107.75%$20.01B
ELANUSElanco Animal Health
-56.11x129.36%$11.17B
VREOFUSVIREO GROWTH INC
-162.48x--$10.90B
AXSMUSAxsome Therap
-53.58x26.93%$10.27B
CURLFUSCuraleaf Holdings, Inc.
-165.08x--$8.59B
BLTEUSBelite Bio
-66.66x29.87%$6.82B
DFTXUSDefinium Therapeutics
-13.95x53.61%$4.94B
MANEUSVeraDermics
-46.36x97.44%$4.83B
EWTXUSEdgewise Therapeutics
-22.67x137.29%$4.47B
AMLXUSAmylyx Pharmaceuticals
-24.87x1.76%$3.78B
TARSUSTarsus Pharmaceuticals
-71.72x34.17%$3.33B
ELVNUSEnliven Therapeutics
-31.24x1.17%$3.31B
RGCUSRegencell Bioscience
-433.71x--$3.06B
MBXUSMBX Biosciences
-25.58x30.54%$2.67B
GPCRUSStructure Therapeutics
-11.95x102.05%$2.57B
SUPNUSSupernus Pharma
-22.90x70.59%$2.52B
TRLVUSTrulieve Cannabis
-4.99x198.82%$2.36B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.